Literature DB >> 11502314

Mortality in patients with coeliac disease and their relatives: a cohort study.

G Corrao1, G R Corazza, V Bagnardi, G Brusco, C Ciacci, M Cottone, C Sategna Guidetti, P Usai, P Cesari, M A Pelli, S Loperfido, U Volta, A Calabró, M Certo.   

Abstract

BACKGROUND: Although previous studies have shown increased mortality in patients with coeliac disease and their relatives, no data are available in relation to different patterns of clinical presentation. We assessed mortality in patients with coeliac disease and their first-degree relatives.
METHODS: We enrolled, in a prospective cohort study, 1072 adult patients with coeliac disease consecutively diagnosed in 11 gastroenterology units between 1962 and 1994, and their 3384 first-degree relatives. We compared the number of deaths up to 1998 with expected deaths and expressed the comparison as standardised mortality ratio (SMR) and relative survival ratio.
FINDINGS: 53 coeliac patients died compared with 25.9 expected deaths (SMR 2.0 [95% CI 1.5-2.7]). A significant excess of mortality was evident during the first 3 years after diagnosis of coeliac disease and in patients who presented with malabsorption symptoms (2.5 [1.8-3.4]), but not in those diagnosed because of minor symptoms (1.1 [0.5-2.2]) or because of antibody screening (1.2 [0.1-7.0]). SMR increased with increasing delay in diagnosis and for patients with poor compliance with gluten-free diet. Non-Hodgkin lymphoma was the main cause of death. No excess of deaths was recorded in relatives with coeliac disease.
INTERPRETATION: Prompt and strict dietary treatment decreases mortality in coeliac patients. Prospective studies are needed to clarify the progression of mild or symptomless coeliac disease and its relation to intestinal lymphoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502314     DOI: 10.1016/s0140-6736(01)05554-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  126 in total

1.  European and North American populations should be screened for coeliac disease.

Authors:  A Fasano
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

2.  Coeliac disease: is case finding the correct ethical and logistical approach?

Authors:  D S Sanders
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

3.  From hyperplasia to T cell lymphoma.

Authors:  N Cerf-Bensussan; N Brousse; C Cellier
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 4.  Celiac disease. CME update for family physicians.

Authors:  Shane M Devlin; Christopher N Andrews; Paul L Beck
Journal:  Can Fam Physician       Date:  2004-05       Impact factor: 3.275

5.  Population based screening for coeliac disease: patient's choice or doctor's decision.

Authors:  S Ishaq
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

6.  Screening for celiac disease in average-risk and high-risk populations.

Authors:  Saurabh Aggarwal; Benjamin Lebwohl; Peter H R Green
Journal:  Therap Adv Gastroenterol       Date:  2012-01       Impact factor: 4.409

Review 7.  Hematologic manifestations of celiac disease.

Authors:  Thorvardur R Halfdanarson; Mark R Litzow; Joseph A Murray
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

8.  Screening of tissue transglutaminase antibody in healthy blood donors for celiac disease screening in the Turkish population.

Authors:  Gonca Tatar; Rengin Elsurer; Halis Simsek; Yasemin H Balaban; Gulsen Hascelik; Osman I Ozcebe; Yahya Buyukasik; Cenk Sokmensuer
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

9.  Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience.

Authors:  A Al-Toma; W H M Verbeek; M Hadithi; B M E von Blomberg; C J J Mulder
Journal:  Gut       Date:  2007-04-30       Impact factor: 23.059

Review 10.  Epidemiology of Hodgkin's disease and non-Hodgkin's lymphoma.

Authors:  A J Swerdlow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.